Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

LYMPHOMA

Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma

Leukemia volume 36, pages 583–587 (2022)Cite this article

Subjects

Mantle cell lymphoma is characterized by the primary CCND1 deregulation caused by the t(11;14)(q13;q32) translocation. In addition, SOX11 had been described as one of the most relevant oncogenes contributing to the pathogenesis of mantle cell lymphoma (MCL) [1]. In particular, high SOX11 expression is restricted to conventional MCL (cMCL) cases, and represents a diagnostic biomarker to differentiate this MCL subtype from the less aggressive leukemic non-nodal MCL (nnMCL) and other lymphoproliferative disorders [2]. Although the consequences of SOX11 overexpression are well described [1], its causes remain widely unknown, as SOX11 is not targeted by any genetic alteration [3]. From the epigenetic perspective, the SOX11 promoter is characterized by the expected presence of activating histone modifications [4]. In 2016, we identified a distant super-enhancer 624–653 kilobases (Kb) downstream SOX11 which becomes activated and creates a three-dimensional (3D) loop structure with the SOX11 locus [5]. Here, we have performed a detailed epigenetic dissection of this distant super-enhancer to shed additional light into the mechanisms underlying SOX11 expression in cMCL.

Overall, our study dissects the SOX11 super-enhancer and identifies a small accessible region exclusively active in SOX11-positive MCL. These findings represent an additional step in the path toward understanding the causes underlying SOX11 upregulation in MCL, although further studies are required to completely elucidate the factors and chain of events associated with this oncogenic activation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Chromosome conformation and chromatin activity at the SOX11 locus in MCL cases.
Fig. 2: Multi-omic dissection of the SOX11 super-enhancer region.

References

  1. Beekman R, Amador V, Campo E. SOX11, a key oncogenic factor in mantle cell lymphoma. Curr Opin Hematol. 2018;25:299–306.

    Article  CAS  Google Scholar 

  2. Navarro A, Clot G, Martínez-Trillos A, Pinyol M, Jares P, González-Farré B, et al. Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier. Haematologica. 2017;102:e360–e363.

    Article  CAS  Google Scholar 

  3. Nadeu F, Martin-Garcia D, Clot G, Díaz-Navarro A, Duran-Ferrer M, Navarro A, et al. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood. 2020;136:1419–32.

    Article  CAS  Google Scholar 

  4. Vegliante MC, Royo C, Palomero J, Salaverria I, Balint B, Martín-Guerrero I, et al. Epigenetic activation of SOX11 in lymphoid neoplasms by histone modifications. PLoS ONE. 2011;6:e21382.

    Article  CAS  Google Scholar 

  5. Queirós AC, Beekman R, Vilarrasa-Blasi R, Duran-Ferrer M, Clot G, Merkel A, et al. Decoding the DNA methylome of mantle cell lymphoma in the light of the entire B cell lineage. Cancer Cell. 2016;30:806–21.

    Article  Google Scholar 

  6. Flavahan WA, Drier Y, Liau BB, Gillespie SM, Venteicher AS, Stemmer-Rachamimov AO, et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature. 2016;529:110–4.

    Article  CAS  Google Scholar 

  7. Vilarrasa-Blasi R, Soler-Vila P, Verdaguer-Dot N, Russiñol N, Di Stefano M, Chapaprieta V, et al. Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation. Nat Commun. 2021;12:651.

    Article  CAS  Google Scholar 

  8. Ernst J, Kellis M. ChromHMM: automating chromatin-state discovery and characterization. Nat Methods. 2012;9:215–6.

    Article  CAS  Google Scholar 

  9. Dunham I, Kundaje A, Aldred SF, Collins PJ, Davis CA, Doyle F, et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57–74.

    Article  CAS  Google Scholar 

  10. Anantharaman A, Lin I-J, Barrow J, Liang SY, Masannat J, Strouboulis J, et al. Role of Helix-Loop-Helix proteins during differentiation of erythroid cells. Mol Cell Biol. 2011;31:1332–43.

    Article  CAS  Google Scholar 

  11. Vegliante MC, Palomero J, Perez-Galan P, Roue G, Castellano G, Navarro A, et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood. 2013;121:2175–85.

    Article  CAS  Google Scholar 

  12. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. Nat Immunol. 2007;8:463–70.

    Article  CAS  Google Scholar 

  13. Walter K, Bonifer C, Tagoh H. Stem cell-specific epigenetic priming and B cell–specific transcriptional activation at the mouse Cd19 locus. Blood. 2008;112:1673–82.

    Article  CAS  Google Scholar 

  14. Albero R, Enjuanes A, Demajo S, Castellano G, Pinyol M, García N, et al. Cyclin D1 overexpression induces global transcriptional downregulation in lymphoid neoplasms. J Clin Investig. 2018;128:4132–47.

    Article  Google Scholar 

  15. Mohanty A, Sandoval N, Phan A, Nguyen TV, Chen RW, Budde E, et al. Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. Blood. 2019;133:306–18.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by research funding from the Spanish Ministerio de Ciencia, Innovación y Universidades through SAF2017-86126-R (to JIM-S), RTI2018-094274-B-I00 and PMP15/00007 which is part of Plan Nacional de I + D + I and co-financed by the ISCIII-Sub-Directorate General for Evaluation and the European Regional Development Fund (FEDER-“Una manera de Hacer Europa”) (to EC), and the National Institutes of Health, National Cancer Institute “Molecular Diagnosis, Prognosis, and Therapeutic Targets in Mantle Cell Lymphoma” (P01CA229100 to EC). Furthermore, the authors would like to thank the support of the Generalitat de Catalunya Suport Grups de Recerca AGAUR 2017-SGR-736 (to JIM-S), 2017-SGR-1142 (to EC) and 2017-SGR-468 (to MAMR), the Accelerator award CRUK/AIRC/AECC joint funder-partnership, the CERCA Programme/Generalitat de Catalunya and CIBERONC (CB16/12/00225, CB16/12/00334 and CB16/12/00489). RV-B (BES-2013-064328) was supported by a predoctoral FPI Fellowship from the Spanish Government. EC is an Academia researcher of the Catalan Institution for Research and Advanced Studies (ICREA). The authors thank the Barcelona Supercomputing Center for access to computational resources. This work was developed at the Centro Esther Koplowitz (CEK, Barcelona, Spain).

Author information

Authors and Affiliations

  1. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

    Roser Vilarrasa-Blasi, Núria Verdaguer-Dot, Renée Beekman, Vicente Chapaprieta, Marta Kulis, Ana C. Queirós, Sílvia Beà, Dolors Colomer, Elías Campo & José Ignacio Martin-Subero

  2. Hospital Clínic de Barcelona and Departament de Fonaments Clínics, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain

    Roser Vilarrasa-Blasi, Sílvia Beà, Dolors Colomer, Elías Campo & José Ignacio Martin-Subero

  3. Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA

    Laura Belver & Adolfo Ferrando

  4. Josep Carreras Leukaemia Research Institute, IJC Building, Campus ICO-Germans Trias i Pujol, Barcelona, Spain

    Laura Belver & Maribel Parra

  5. CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain

    Paula Soler-Vila & Marc A. Marti-Renom

  6. Área de Oncología, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad de Navarra, Pamplona, Spain

    María José Calasanz, Xabier Agirre & Felipe Prosper

  7. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain

    María José Calasanz, Xabier Agirre, Felipe Prosper, Sílvia Beà, Dolors Colomer, Elías Campo & José Ignacio Martin-Subero

  8. Servicio de Hematología, Clínica Universidad de Navarra, Pamplona, Spain

    Felipe Prosper

  9. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

    Marc A. Marti-Renom & José Ignacio Martin-Subero

Authors
  1. Roser Vilarrasa-Blasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Núria Verdaguer-Dot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laura Belver
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paula Soler-Vila
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Renée Beekman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vicente Chapaprieta
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marta Kulis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ana C. Queirós
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Maribel Parra
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. María José Calasanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Xabier Agirre
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Felipe Prosper
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Sílvia Beà
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Dolors Colomer
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Marc A. Marti-Renom
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Adolfo Ferrando
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Elías Campo
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. José Ignacio Martin-Subero
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

RV-B, coordinated and performed FISH, in situ Hi–C, targeted MS, histone mark and ATAC-seq data generation and computational data analysis. NV-D, performed and supported FISH, in situ Hi–C, histone mark, and ATAC-seq data generation. LB, and AF, supported targeted MS data generation and analysis. PS-V, and MAM-R, supported in situ Hi–C computational data analysis. VC contributed in histone marks and ATAC-seq data analysis. MK, ACQ, and RB participated in DNA methylome data generation and analyses as well as in the study data interpretation. MP, MJC, XA, FP, SB, DC, EC, contributed with key reagents as well as sample collection and their biological and clinical annotation. RV-B and JIM-S directed the research and wrote the manuscript.

Corresponding authors

Correspondence to Roser Vilarrasa-Blasi or José Ignacio Martin-Subero.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vilarrasa-Blasi, R., Verdaguer-Dot, N., Belver, L. et al. Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma. Leukemia 36, 583–587 (2022). https://doi.org/10.1038/s41375-021-01389-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-021-01389-w

This article is cited by

Search

Advanced search

Quick links